The use of a biomarker in the preparation of a diagnostic product and therapeutic
drug for Schistosomiasis
japonica, wherein the biomarker is
uridine or Upase1, which is a key
enzyme in
uridine metabolism. By means of a large number of studies, changes in metabolites in early and chronic stages of Schistosomiasis
japonica infection were analyzed to screen for characteristic metabolites and metabolic pathways. By means of exploring and analyzing abundant region-specific changes of a plurality of metabolites in the liver of mice at different infection stages, it was surprisingly found that Upase1, which is a key
enzyme in
uridine metabolism, was significantly up-regulated 6 weeks after infection, and the hepatic uridine level was negatively correlated with the abundance of a plurality of lipid-related metabolites. Moreover,
verification, and specificity and sensitivity studies confirmed that uridine or Upase1, which is a key
enzyme in uridine
metabolism, could be used as a characteristic marker molecule for Schistosomiasis
japonica infection, and for developing diagnostic products for Schistosomiasis japonica. Further studies have found that
in vitro supplementation with uridine can exert an anti-fibrotic role, and uridine can be used as a therapeutic
drug for Schistosomiasis japonica.